HIV Subtypes and Drug-resistance-associated Mutations in US Blood Donors, 2015-2020

Overview

Journal Open Forum Infect Dis

Specialty Infectious Diseases

Date 2024 Jul 12

PMID 38994445

Authors

Brian Custer

Eda Altan

Leilani Montalvo

Alison Coyne

Eduard Grebe

Xutao Deng

Mars Stone

Eric Delwart

Sonia Bakkour

Benyam Hailu

Rita Reik

Debra Kessler

Susan L Stramer

Michael P Busch

Affiliations

Soon will be listed here.

Abstract

Background: Monitoring genotypes of HIV infections in blood donors may provide insights into infection trends in the general population.

Methods: HIV RNA was extracted from plasma samples of blood donors confirmed as HIV positive by blood screening nucleic acid and antibody tests. HIV genome target regions were amplified using nested real time-polymerase chain reaction followed by next-generation sequencing. Sequences were compared to those in the Los Alamos National Laboratory (LANL) database. Sequences were also assessed for drug resistance mutations (DRM) using the Stanford HIV DRM Database.

Results: From available HIV-positive donations collected between 1 September 2015 and 31 December 2020, 563 of 743 (75.8%) were successfully sequenced; 4 were subtype A, 543 subtype B, 5 subtype C, 1 subtype G, 5 circulating recombinant forms (CRF), and 2 were subtype B and D recombinants. Overall, no significant differences between blood donor and available LANL genotypes were found, and the genotypes of newly acquired versus prevalent HIV infections in donors were similar. The proportion of non-B subtypes and CRF remained a small fraction, with no other subtype or CRF representing more than 1% of the total. DRM were identified in 122 (21.6%) samples with protease inhibitor, nucleoside reverse transcriptase inhibitor and non-nucleoside reverse transcriptase inhibitor DRMs identified in 4.9%, 4.6% and 14.0% of samples, respectively.

Conclusions: HIV genetic diversity and DRM in blood donors appear representative of circulating HIV infections in the US general population and may provide more information on infection diversity than sequences reported to LANL, particularly for recently transmitted infections.

References

Delwart E, Orton S, Parekh B, Dobbs T, Clark K, Busch M . Two percent of HIV-positive U.S. blood donors are infected with non-subtype B strains. AIDS Res Hum Retroviruses. 2004; 19(12):1065-70. DOI: 10.1089/088922203771881149. View

Quiner C, Bruhn R, Grebe E, Di Germanio C, Kessler D, Reik R . Recently acquired infection among HIV-seropositive donors in the US from 2010-2018. Transfusion. 2020; 60(10):2340-2347. PMC: 11630110. DOI: 10.1111/trf.16032. View

Steele W, Dodd R, Notari E, Xu M, Nelson D, Kessler D . Prevalence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in United States blood donations, 2015 to 2019: The Transfusion-Transmissible Infections Monitoring System (TTIMS). Transfusion. 2020; 60(10):2327-2339. DOI: 10.1111/trf.16005. View

Ragonnet-Cronin M, Hodcroft E, Hue S, Fearnhill E, Delpech V, Leigh Brown A . Automated analysis of phylogenetic clusters. BMC Bioinformatics. 2013; 14:317. PMC: 4228337. DOI: 10.1186/1471-2105-14-317. View

OKeefe K, Pipkin S, Fatch R, Scheer S, Liegler T, McFarland W . Non-B variants of HIV-1 in San Francisco, California. Infect Genet Evol. 2020; 90:104677. PMC: 10686190. DOI: 10.1016/j.meegid.2020.104677. View

Dwyre D, Fernando L, Holland P . Hepatitis B, hepatitis C and HIV transfusion-transmitted infections in the 21st century. Vox Sang. 2010; 100(1):92-8. DOI: 10.1111/j.1423-0410.2010.01426.x. View

Kosakovsky Pond S, Poon A, Velazquez R, Weaver S, Hepler N, Murrell B . HyPhy 2.5-A Customizable Platform for Evolutionary Hypothesis Testing Using Phylogenies. Mol Biol Evol. 2019; 37(1):295-299. PMC: 8204705. DOI: 10.1093/molbev/msz197. View

Steele W, Dodd R, Notari E, Haynes J, Anderson S, Williams A . HIV, HCV, and HBV incidence and residual risk in US blood donors before and after implementation of the 12-month deferral policy for men who have sex with men. Transfusion. 2021; 61(3):839-850. DOI: 10.1111/trf.16250. View

Oster A, Pieniazek D, Zhang X, Switzer W, Ziebell R, Mena L . Demographic but not geographic insularity in HIV transmission among young black MSM. AIDS. 2011; 25(17):2157-65. DOI: 10.1097/QAD.0b013e32834bfde9. View

10.

Gibson K, Steiner M, Kassaye S, Maldarelli F, Grossman Z, Perez-Losada M . A 28-Year History of HIV-1 Drug Resistance and Transmission in Washington, DC. Front Microbiol. 2019; 10:369. PMC: 6418020. DOI: 10.3389/fmicb.2019.00369. View

11.

Ragonnet-Cronin M, Benbow N, Hayford C, Poortinga K, Ma F, Forgione L . Sorting by Race/Ethnicity Across HIV Genetic Transmission Networks in Three Major Metropolitan Areas in the United States. AIDS Res Hum Retroviruses. 2020; 37(10):784-792. PMC: 8573809. DOI: 10.1089/AID.2020.0145. View

12.

Delwart E, Kuhns M, Busch M . Surveillance of the genetic variation in incident HIV, HCV, and HBV infections in blood and plasma donors: implications for blood safety, diagnostics, treatment, and molecular epidemiology. J Med Virol. 2006; 78 Suppl 1:S30-5. DOI: 10.1002/jmv.20604. View

13.

Tamura K, Stecher G, Kumar S . MEGA11: Molecular Evolutionary Genetics Analysis Version 11. Mol Biol Evol. 2021; 38(7):3022-3027. PMC: 8233496. DOI: 10.1093/molbev/msab120. View

14.

Grebe E, Busch M, Notari E, Bruhn R, Quiner C, Hindes D . HIV incidence in US first-time blood donors and transfusion risk with a 12-month deferral for men who have sex with men. Blood. 2020; 136(11):1359-1367. PMC: 7483431. DOI: 10.1182/blood.2020007003. View

15.

Duong Y, Kassanjee R, Welte A, Morgan M, De A, Dobbs T . Recalibration of the limiting antigen avidity EIA to determine mean duration of recent infection in divergent HIV-1 subtypes. PLoS One. 2015; 10(2):e0114947. PMC: 4339840. DOI: 10.1371/journal.pone.0114947. View

16.

Tamura K, Nei M, Kumar S . Prospects for inferring very large phylogenies by using the neighbor-joining method. Proc Natl Acad Sci U S A. 2004; 101(30):11030-5. PMC: 491989. DOI: 10.1073/pnas.0404206101. View

17.

Gibson K, Steiner M, Kassaye S, Maldarelli F, Grossman Z, Perez-Losada M . Corrigendum: A 28-Year History of HIV-1 Drug Resistance and Transmission in Washington, DC. Front Microbiol. 2019; 10:2590. PMC: 6861842. DOI: 10.3389/fmicb.2019.02590. View

18.

Fogel J, Sivay M, Cummings V, Wilson E, Hart S, Gamble T . HIV drug resistance in a cohort of HIV-infected MSM in the United States. AIDS. 2019; 34(1):91-101. PMC: 7144622. DOI: 10.1097/QAD.0000000000002394. View

19.

McClung R, Oster A, Ocfemia M, Saduvala N, Heneine W, Johnson J . Transmitted Drug Resistance Among Human Immunodeficiency Virus (HIV)-1 Diagnoses in the United States, 2014-2018. Clin Infect Dis. 2021; 74(6):1055-1062. PMC: 9630858. DOI: 10.1093/cid/ciab583. View

20.

Tamura K, Nei M . Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. Mol Biol Evol. 1993; 10(3):512-26. DOI: 10.1093/oxfordjournals.molbev.a040023. View